Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatiti
Go back to Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatiti| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1125.65 -23.71 (2.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1149.36 | 52 Week High | $88.16 | |||
| Open | $1133.00 | 52 Week Low | $67.88 | |||
| Day High | $1134.53 | P/E | 260.57 | |||
| Day Low | $1113.55 | EPS | $4.32 | |||
| Volume | 982,743 | |||||
